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Endothelial cell dysfunction (ECD) is a common feature of
chronic renal failure (CRF). Defective nitric oxide (NO)
generation due to decreased endothelial NO synthase (eNOS)
activity is a crucial parameter characterizing ECD. L-arginine is
the sole precursor for NO biosynthesis. Among several
transporters that mediate L-arginine uptake, cationic
amino-acid transporter-1 (CAT-1) acts as the specific arginine
transporter for eNOS. Our hypothesis implies that CAT-1 is a
major determinant of eNOS activity in CRF. We studied
glomerular and aortic arginine uptake, CAT-1, and CAT-2
messenger ribonucleic acid (mRNA) expression, and CAT-1
protein in: (a) rats 6 weeks following 5/6 nephrectomy (CRF),
(b) sham-operated animals, and (c) rats with CRF treated
orally with either atorvastatin or arginine in drinking water
(modalities which have been shown to enhance eNOS activity
and improve endothelial function). Both glomerular and
aortic arginine transport were significantly decreased in CRF.
Treatment with either arginine or atorvastatin abolished the
decrease in arginine uptake in CRF rats. Using reverse
transcriptase-polymerase chain reaction and Northern
blotting, we found a significant increase in glomerular and
aortic CAT-1 mRNA expression in CRF. Western blotting
revealed that CAT-1 protein was decreased in CRF, but
remained intact following arginine and atorvastatin
administration. Renal and systemic arginine uptake is
attenuated in CRF, through modulation of CAT-1 protein.
These findings provide a possible novel mechanism to eNOS
inactivation and endothelial dysfunction in uremia.
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Endothelial cell dysfunction (ECD) is a common precursor
and denominator of patients with chronic renal failure
(CRF). This syndrome is currently interpreted as encom-
passing disturbances in several functions: the barrier function
of vascular endothelium, its impaired antithrombogenic
properties, blunted angiogenic capacity, inappropriate regu-
lation of vascular smooth muscle tonicity, proliferative
capacity, and migratory properties.1 Accumulated evidence
suggests that many of these abnormalities are linked to the
capacity of the constitutive, Ca2þ /calmodulin-sensitive nitric
oxide (NO) synthase (NOS) to generate adequate quantities
of NO.2 Indeed, reduction in NO generation has been
reported in both experimental CRF and peritoneal, and
hemodialysis patients.3–6 Abnormal function of the endo-
thelial NOS (eNOS) system that results in ECD includes:
decreased eNOS expression, alteration of NO signaling,
destruction of NO by reactive oxygen species, and impaired
availability of cofactors.7 Our interest in this area is focused
on the role of intracellular arginine availability in governing
eNOS activity, thus affecting endothelial function. In vitro
studies performed by Baylis et al.8,9 suggest that arginine
uptake is decreased in renal failure. Moreover, they have
shown that serum of uremic patients has the capacity to
inhibit arginine uptake by cultured endothelial cells, an effect
attributed to urea uptake by endothelial cells via urea
transporter type B.
Among several transport systems that mediate L-arginine
uptake (yþ, b0,þ , B0,þ , and yþ L), system yþ is widely
expressed and considered to be a major arginine transporter
in most tissues and cells. Encoded by cationic amino-acid
transporters (CAT)-1, CAT-2, and CAT-3, system yþ is
characterized by high affinity for cationic amino acids,
sodium independence, and stimulation of transport by
substrate on the opposite (trans) side of the membrane.10,11
Accumulated evidence from our laboratory and others
suggest that each transporter has affinity to a specific NOS
isoform. We have previously shown that arginine uptake by
tubules or glomeruli harvested from rats subjected to
ischemia and reperfusion or to sepsis, two experimental
models characterized by activation of the inducible
NOS, exhibit augmented arginine uptake, associated with
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upregulation of CAT-2.12,13 In contrast, we have also
suggested that increased arginine uptake through upregula-
tion of CAT-1 may contribute to the pathogenesis of diabetic
hyperfiltration, via activation of eNOS.14 Schafer et al.15 have
shown that suppression of the endothelium-mediated
microvascular vasodilation by dexamethasone involves
downregulation of eNOS and CAT-1. Moreover, CAT-1 and
eNOS were found to be colocalized in a caveolar complex;16
therefore, this complex has been suggested to serve as a
mechanism for channeling of newly acquired extracellular
arginine to eNOS, for NO synthesis. In the aggregate, it is
believed that arginine is delivered to eNOS predominantly
by CAT-1.
Experiments described herein were designed to determine
whether glomerular and aortic arginine uptake are altered in
an in vivo model of CRF and to elucidate whether these
changes are related to the specific eNOS arginine transporter
CAT-1 mRNA expression and protein abundance in these
tissues. In addition, we studied the beneficial effects of
arginine and statins, two modalities previously shown to
improve endothelial function, on the above parameters,
aiming to link our findings to ECD in CRF.
RESULTS
Effects of atorvastatin and L-arginine on creatinine clearance
To consolidate previous observations and validate the
therapeutic efficiency of arginine and atorvastatin in CRF,
creatinine clearance (CCr) was measured in all experimental
groups (Figure 1). CRF resulted in a significant decrease in
CCr (0.2370.04 vs 0.5570.05 ml/min/100 g body weight
(BW), Po0.01). Administration of L-arginine or atorvastatin
significantly attenuated the decrease in CCr in CRF animals
(0.4770.09 and 0.4270.08 ml/min/100 g BW, respectively).
Aortic and glomerular arginine transport
Initially, we wished to explore the possibility that CRF affects
the characteristics of yþ system, the predominant arginine
uptake system.
Figure 2a and b demonstrates that, in aortic rings and
glomeruli harvested from animals subjected to 5/6 nephre-
ctomy, arginine transport system remained sodium indepen-
dent. Excess concentration of lysine strongly inhibited
L-arginine uptake, while the neutral amino acid methionine
was found to be a poor inhibitor. In addition, we
characterized the kinetics of L-arginine transport in both
tissues by measuring the saturable uptake of L-arginine
(0–1 mM). The plots of L-arginine uptake as a function of
extracellular L-arginine concentration are shown in Figure 3a
and b. A high-affinity transporter was found to be present
with a Km of 120 and 125 mM in aortic rings and glomeruli,
respectively. These data establish that, in glomeruli and aortic
rings from rats with CRF, system yþ remains the predomi-
nant arginine transport system, with kinetic properties that
resemble those of CAT-1 and CAT-2.
The next set of experiments was designed to explore a
possible effect of CRF on yþ system and the impact of agents
that have been shown to improve endothelial function via
modulation of the NO system, namely arginine and statins.
We have chosen to perform these experiments in both aortic
and renal tissues in order to explore differences between renal
and systemic circulation. When compared to normal rats,
CRF induced a significant (B50%) decrease in both aortic
and glomerular arginine uptake. Treatment of CRF rats with
either arginine or atorvastatin completely abolished this























Figure 1 | Effect of atorvastatin and arginine on GFR indexed by
CCr in CRF. Results shown are mean7s.e.m. *Po0.05 vs controls


















































Figure 2 | Sodium independence and cis-inhibition by lysine of
(a) aortic and (b) glomerular arginine uptake in CRF rats. Uptake
of radiolabeled arginine (L-[3H]arginine) by freshly harvested
glomeruli and aortic rings from CRF animals, in the presence of either
140 mM sodium chloride or 140 mM choline chloride and either lysine
or methionine 10 mM added to the transport solution. Data are
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Figure 3 | Concentration dependence of L-arginine uptake by
(a) aortic rings and (b) glomeruli from CRF rats. Uptake of
[3H]arginine was measured, for 1 min in freshly harvested glomeruli
and aortic rings from CRF rats over a range of concentrations
(0–1 mM). Data are presented as the mean7s.e.m. of four different
experiments.
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Regulation of CAT-1 and CAT-2 gene expression in CRF
To determine whether the observed CRF-induced changes in
arginine uptake are associated with similar directional
changes in mRNA levels for CAT family of transporters,
total aortic and glomerular RNA was analyzed by reverse
transcriptase-polymerase chain reaction (RT-PCR) to amplify
portions of CAT-1 and CAT-2. We identified complementary
deoxyribonucleic acid (cDNA) encoding both CAT-1 and
CAT-2 in the glomeruli and aortic rings harvested from
control rats. Surprisingly, CRF significantly augmented the
expression of CAT-1 mRNA in both aortic rings and
glomeruli. Treating CRF rats with either arginine or
atorvastatin abolished the increase in CAT-1 mRNA in the
aortic strips (Figure 5a and b), while no significant effect was
observed in glomeruli (Figure 6a and b). CAT-2 remained
unchanged in CRF rats (data not shown).
To further confirm this observation, Northern blotting
was performed. CRF rats exhibited a significant increase in
aortic and glomerular steady-state CAT-1 mRNA levels,
which were not affected by cotreatment with either arginine
or atorvastatin (Figure 7a–d).
Glomerular and aortic CAT-1 protein in CRF
To further explore a possible role for CAT-1 in arginine traffic
in CRF, we examined CAT-1 protein levels. CAT-1 protein
was identified as B90 kDa, in both glomerular and aortic
tissues. Studies on CAT-1 protein have been hampered by
difficulties in generating anti CAT-1 antibodies and some
variability in the band’s size, probably reflecting different
degrees of glycosylation of the protein, as shown previously
for other transporters.17 To verify our findings, we used anti
CAT-1 antibodies directed against two different epitopes.
Both antibodies yielded a similar, B90 kDa band. The
specificity of the antibody was demonstrated by incubating
our membranes with anti-CAT-1 antibody in the presence of
the antigenic peptide, which indeed blocked the appearance
of the 90-kDa protein bands. We found that CAT-1
abundance was significantly decreased in tissues harvested
from CRF rats. Treatment with either atorvastatin or arginine
prevented this phenomenon (Figure 8a–d). Western blotting



























































Figure 4 | Uptake of radiolabeled arginine (L-[3H]arginine) by
(a) aortic rings and (b) freshly harvested glomeruli from the
various experimental groups. Data are presented as the
mean7s.e.m. of at least five different experiments. *Po0.05 vs


























Figure 5 | (a) Ethidium-stained agarose electrophoresis gel
showing PCR-amplified CAT-1 and GAPDH cDNA of aortic rings
harvested from the same experimental groups. Data are
representative of three different experiments. CTL: controls, CRF:
chronic renal failure, ARG: L-arginine, ATORVA: atorvastatin.
(b) Relative amount of CAT-1 mRNA quantitated by densitometry and
expressed as the CAT/GAPDH ratio of the same experiments shown in
Figure 4a. Data are presented as the mean7s.e.m. of three different





























Figure 6 | (a) Ethidium-stained agarose electrophoresis gel
showing PCR-amplified CAT-1 and GAPDH cDNA of glomeruli
harvested from the same experimental groups. Data are
representative of three different experiments. CTL: controls, CRF:
chronic renal failure, ARG: L-arginine, ATORVA: atorvastatin.
(b) Relative amount of CAT-1 mRNA quantitated by densitometry and
expressed as CAT/GAPDH ratio of the same experiments shown in
Figure 5a. Data are presented as the mean7s.e.m. of three different




























































Figure 7 | Northern blot analysis of (a) aortic and (b) glomerular
CAT-1 and GAPDH mRNA from all experimental groups. These
blots are representative of four different experiments. CTL: controls,
CRF: chronic renal failure, ARG: L-arginine, ATORVA: atorvastatin. (c, d)
Graphic representation of relative changes in mRNA levels. The ratio
of the signal of the 7.9 kb CAT-1 mRNA over the signal of GAPDH
mRNA in (c) aortic rings and (d) glomeruli was plotted against the
appropriate experimental groups. *Po0.05 vs control (mean7s.e.m.
of four different experiments).
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DISCUSSION
The present study demonstrates that both glomerular and
aortic arginine uptake are attenuated in an in vivo model of
CRF. Molecular analysis reveals that while CAT-2 mRNA
levels are not altered, those of CAT-1 are paradoxically
increased. In contrast, CAT-1 protein abundance is decreased.
Both arginine and atorvastatin prevented the decrease in
arginine uptake velocities and CAT-1 protein level. These
data suggest a novel mechanism for the decrease in eNOS
activity and thus for endothelial dysfunction, which are
characteristic of CRF. In addition, they provide an expla-
nation for amelioration of endothelial function mediated by
arginine or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors in CRF.
Our data are consistent with those of a previous study by
Baylis et al.,8,9 who reported a decrease in arginine uptake by
cultured endothelial cells exposed to uremic serum. This
effect was reversed by blocking urea flux, suggesting that urea
inhibits arginine transport. Comparison between the latter
study and ours reveals that the magnitude of the uremic
effect was more pronounced in our experimental model. A
different methodology could serve as an explanation to the
above observation. Substances other than urea, which
account for the uremic milieu, may become apparent in vivo
but not in vitro. Indeed, the same group has reported that
uremic levels of blood urea nitrogen do not alter NO
metabolism in normal rats.18 One plausible candidate is the
endogenous arginine analog asymmetric dimethyl arginine
(ADMA). High extracellular levels of ADMA have been
reported in CRF and were shown to attenuate NO
generation, yet, did not affect arginine uptake in vitro.8 Of
note, in vivo intracellular levels of ADMA in uremic
conditions are unknown, and may be higher than plasma
levels. Therefore, impaired availability of L-arginine induced
by ADMA may impact cellular NO production only when
studied in vivo.
We have tried to elucidate a molecular mechanism to
explain our findings. The fact that the changes observed in
arginine uptake were associated with CAT-1 (but not with
CAT-2) expression strengthens the hypothesis that these
events are mediated by eNOS activity: CAT-1 colocalizes with
eNOS in the endothelial cell caveola, thus acting as a specific
supplier of arginine for eNOS.16 This conclusion bears a
limitation as exclusivity of CAT-1 was not fully established
since we were unable to follow CAT-2 protein. Our data
clearly establish that, in CRF, CAT-1 expression is primarily
regulated at the post-transcriptional level. The question
raised from these studies is why CAT-1 mRNA level increases
in CRF without being translated into more CAT-1 protein.
One can speculate that the increase in CAT-1 mRNA
transcription, or stability, compensates for inefficient trans-
lation, yet fails to sustain adequate CAT-1 protein level. A
similar finding for CAT-1 has been reported in amino-acid-
depleted C6 glia and NRK (normal rat kidney) kidney cells,
when compared with amino-acid-fed cells.19 Future studies
will show if factors besides urea are involved in down-
regulation of CAT-1 protein in CRF.
To further define the relationship between CAT-1 activity
and endothelial function in uremia, we examined the effect of
atorvastatin and arginine on CAT-1 in CRF. It is well
established that the beneficial effects of statins in CRF are
far beyond lipid-lowering properties. They have been shown to
improve vessel stiffness in CRF and inhibit inflammation in
dialysis patients, implying that these agents improve endo-
thelial function.20 Hence, the beneficial effect is complex and
not completely understood. Inhibition of HMG-CoA reductase
results in depleted downstream products of mevalonate, which
are critical elements for post-translational modification of
ubiquitous signaling proteins such as G proteins, guanine
50-triphosphate-binding protein Ras, and Rho family mem-
bers. These effects have been shown to result in augmented
eNOS expression.21,22 Our observation, that atorvastatin has
a beneficial effect on CAT-1, implies the existence of a new
regulatory mechanism by which statins modify eNOS
activity, thus ameliorating endothelial function in CRF.
Given the fact that intracellular levels of L-arginine far
exceed the Km of NOS enzyme, it appears unlikely that the
administration of substrate affects cellular NO production.
Surprisingly, numerous studies unequivocally demonstrated,
both in animals and humans, beneficial effects for arginine
administration on vascular response, including conditions
such as hypercholesterolemia, hypertension, and dia-
betes.23–25 Furthermore, even oral feeding of arginine, which
only doubles plasma arginine levels, was found to have
beneficial effects on atherosclerosis development in choles-
terol-fed rabbits and in hypertensive rats.25,26 Reyes et al.27
examined the effects of dietary L-arginine on renal function
in rats with remnant kidney. They found that administration












































































Figure 8 | Representative Western blot analysis showing
regulation of CAT-1 protein level in freshly harvested (a) aortic
rings and (b) glomeruli from the same experimental groups.
Densitometric analysis of CAT-1 contents from (c) aortic rings and
(d) glomeruli from the various experimental groups. Each bar
represents the mean of the relative density units7s.e. from six
different experiments, *Po0.05 vs control. CTL: controls, CRF:
chronic renal failure, ARG: L-arginine, ATORVA: atorvastatin.
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proteinuria, and higher GFR. This phenomenon, in which
arginine supplementation stimulates NO synthesis despite
saturating intracellular concentrations, can be explained by
our results. We found that oral arginine administration to
CRF rats prevented the decrease in arginine uptake and
preserved CAT-1 protein abundance. If arginine is selectively
introduced to eNOS by CAT-1, then the protective effect of
arginine on CAT-1 can serve as a plausible explanation for
the findings described by Reyes et al.: Thus, it is not solely the
increase in extracellular arginine concentration but rather the
preservation of CAT-1 ability ‘to feed’ eNOS with its
substrate, which may constitute the beneficial effect of
arginine on eNOS activity in CRF.
Being limited in our capacity to attenuate the progression
of chronic kidney disease, the present study suggests that
future efforts should be directed to sustain CAT-1 expression
and activity in order to improve endothelial function in CRF.
Our data support the therapeutic effects of statins and
arginine in patients with CRF.
MATERIALS AND METHODS
Materials
All standard reagents were obtained from Sigma Chemical Co., St. Louis,
MO, USA, unless indicated otherwise. [H3]L-arginine was supplied by
Perkin-Elmer, Life and Analytical Sciences, Boston, MA, USA.
Animals and surgical preparation
All animal experiments described in this study were conducted in
accord with the protocol approved by the institutional committee
on ethics in animal experiments. Studies were performed using male
Wistar rats weighing 200–250 g. Subsequently, rats were segregated
into four groups, respectively:
Group 1: control, sham-operated rats. Group 2: CRF, rats
underwent a two-stage 5/6 nephrectomy (interval of one week).
Following the operation, animals were allowed to recover and have
free access to a standard rat chow and tap water. Experiments were
performed 6 weeks following the second surgery. Group 3: CRFþ
L-arginine: CRF rats were given L-arginine 1% in drinking water, starting
from day 1. Group 4: CRFþ statin: CRF animals were treated with
atorvastatin, 10 mg/kg BW/day in drinking water starting from day 1.
CCr was measured, prior to killing, in all experimental groups as
described previously.28
L-arginine uptake by aortic rings
Uptake of radiolabeled L-arginine in the rat aorta was measured
according to previously described methods with modification.
Immediately after the rat was killed, the aorta was carefully excised
from the left renal artery to the aortic valve ring and placed in ice-
cold HEPES buffer. The vessels were dissected free from adherent
connective tissue and cut into rings (length 3–4 mm). Each segment
was cut longitudinally into halves. To determine arginine transport,
aortic segments of each experimental group were incubated and
shaken for 10 min in HEPES buffer at pH 7.4, 371C. L-[3H]arginine
and L-arginine, in a final concentration of 1 mM, were added to a
total volume of 2 ml for additional 1 min. The duration of 1 min was
chosen since it was within the linear portion of uptake curves (data
not shown). Transport was terminated by rapidly washing the aortic
rings with ice-cold phosphate-buffered saline (PBS) buffer (four
times, 3 ml/tube). The rings were then dried and solubilized in 1 ml
of 0.5% sodium dodecyl sulfate (SDS) in 0.5 N NaOH. In all, 700ml
of the lysate was used to monitor radioactivity, by liquid scintillation
spectrometry (Betamatic, Kontron, St. Louis, MO, USA). The
remaining 300ml was used for protein content determination by the
Lowry method (Lowry assay Kit, Sigma Co.) To correct for
nonspecific uptake or cell membrane binding, additional studies
were performed in which aortic segments were incubated with
10 mM unlabeled arginine in HEPES buffer, and the associated
radioactivity was subtracted from each data point. Results are
expressed as mean7s.e. of at least five different experiments.
L-arginine uptake by freshly harvested glomeruli
Isolation of glomeruli and arginine uptake was performed essentially
as described previously.12–14 In brief, glomerular suspensions from the
various experimental groups were incubated and shaken for 10 min in
HEPES buffer at pH 7.4, 371C. L-[H3]arginine and L-arginine, in a
final concentration of 1 mM, were added to a total volume of 1 ml for
additional 1 min. Transport activity was terminated by rapidly
washing the cells with ice-cold PBS buffer (four times, 2 ml/tube).
The glomeruli were then dried and solubilized in 1 ml of 0.5% SDS in
0.5 N NaOH. A volume of 700ml of the lysate was used to monitor
radioactivity and the remaining 300ml was used for protein content,
as described in the previous section. Results are expressed as
mean7s.e. of at least five different experiments.
Analysis of mRNA levels for CAT-1 and CAT-2 by RT-PCR
Total cellular RNA was extracted from glomeruli or aortic rings
following the method described by Chomeczynski and Sacchi.29
Reverse transcription was carried out for 1.5 h at 421C, and PCR in
10 buffer for a total of 35 cycles, each of 941C for 1 min, 601C for
1 min, 721C for 2 min, and 7 min (final cycle) (Promega, Madison,
WI). The first pair of primers was designed to bind to a portion of
the rat CAT-1 gene: forward 21-mer, 50-GCCATCGTCAT
CTCCTTCCTG-30, and reverse 21-mer, 50-CCCTCCCTCACCG
TATTTCAC-30 expression. A second pair of primers, which
hybridize to a sequence, common to both CAT-2 and CAT-2A were:
forward 24-mer, 50-AACGTGCTTTTATGCCTTTGT-30, and reverse
23-mer, 50-GGTGACCTGGGACTCGCTCTT-30.30 To exclude the
possibility of contamination by genomic DNA amplification, and to
assess the adequacy of cDNA, experiments were carried out in the
absence of reverse transcriptase. Amplification of glyceraldehyde 3
phosphate dehydrogenase (GAPDH) was performed, respectively.
PCR products were electrophoresed on a 1.6% agarose gel and
visualized by UV-induced fluorescence. All PCR reactions resulted in
the amplification of a single product of the predicted size for CAT-1,
CAT-2/2A, and GAPDH.
Northern blot analysis
Prehybridization for CAT-1 mRNA level was determined by northern
hybridization. In all, 20mg of total RNA was denatured and fractionated
by size on 1.3% formaldehyde-agarose gel. RNA was transferred
overnight, by capillary action, to a nylon membrane (Hybond-N,
Amersham International, Buckinghamshire, UK), and crosslinked by
short-wave ultraviolet illumination. Purified end products of CAT-1 and
GAPDH cDNA (High pureTM PCR product purification Kit) (Boehrin-
ger Mannheim, Germany) were used directly for radiolabeling with
[P32]deoxycytidine triphosphate by a random primer labeling method
(Random primers DNA Labeling System Kit) (Gibco BRL, Gaithers-
burg, MD, USA). After 1 h at 501C, membranes were hybridized
overnight at 501C with the 32P-labeled cDNA. Membranes were
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sequentially washed twice in 1 standard sodium citrate (SSC), 0.1%
SDS for 15 min, at room temperature, once in 1 SSC, 0.1% SDS for
15 min at 501C, followed by 0.5 SSC, 0.1% SDS at 551C for 30 min,
and then washed at high stringency in 0.1 SSC, 0.1% SDS at 571C for
15 min. Autoradiography was carried out with Kodak XAR film (Kodak,
Rochester, NY, USA) for 24–48 h at 801C. Relative mRNA abundance
was quantified by measuring the density of the exposed film with a
densitometer (BIS 202D) (Fuji, Tokyo, Japan). CAT-1 mRNA level was
normalized to GAPDH mRNA and expressed in arbitrary units as the
ratio of CAT-1 to GAPDH expression in four different experiments.
CAT-1 protein quantification by Western blotting
CAT-1 protein expression in aortas and glomeruli was determined
by Western blot analysis. Briefly, excised aortas and glomeruli were
separately placed in ice-cold PBS lysis buffer (pH 7.4), containing
protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 4.5 mM
leupeptin, and 5 mM aprotinin) (ICN Biomedicals Inc., Irvine, CA,
USA), 0.01% Triton X-100, and 0.1% SDS, mechanically homo-
genized, and left on ice for 45 min. Homogenates were subsequently
centrifuged (13 000 r.p.m. for 10 min, at 41C). Cell lysates were
stored in aliquots in 701C. A membrane fraction was obtained by
adding to the pellet an equal volume of lysis buffer supplemented by
Tween-20 (0.25%) to solubilize. The protein content of each sample
was determined by the method of Lowry. Equal amounts of protein
(30mg) were prepared in sample buffer (2% SDS, 0.01%
bromophenol blue, 25% glycerol, 0.0625 M Tris HCL, pH 6.8, 5%
mercaptoethanol) and analyzed on a 7.5% SDS–polyacrylamide
electrophoresis gel. The gel was transferred onto Hybond ECL
nitrocellulose membranes (Amersham Corp.), and blocked in PBS
with bovine serum albumin (PBS-T) containing 5% nonfat dried
milk at room temperature. Membranes were then incubated with
polyclonal rabbit anti-rat CAT-1 antibodies, 1:500 and 1:200 for
peptide-1 and peptide-2, respectively (synthesized by Dr O Leitner,
Weizmann Institute, Rehovot, Israel), for 1 h at room temperature,
washed, and incubated with secondary horseradish peroxidase-
conjugated goat anti-rabbit antibody (1:10 000) in PBS-T for 1 h.
Membranes were washed three times, for 5 min each, in PBS-T.
Membranes were then stripped and reprobed with b-actin. CAT-1
was detected by enhanced chemiluminescence (Kodak X-OMAT AR
film) and quantified by densitometry.
Statistical analysis
Means7s.e. one-way analysis of variance for comparison between
groups and Student’s t-test between two groups were computed and
used to assess the statistical significance. P-values o0.05 were
considered to be statistically significant.
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